Endocrinology News

Professional fulfillment can be achieved through a culture of wellness, efficiency of practice in the workplace and personal resilience, according to a speaker at the Ending Clinician Burnout Global Summit.

Young children at high genetic risk for type 1 diabetes may be more likely to progress to the disease based on their dietary intake, according to a presenter at the European Association for the Study of Diabetes annual meeting.

CHICAGO — Hormone therapy is beneficial for some women beyond age 65 years to treat ongoing menopausal symptoms that affect their quality of life, according to research reported at the Annual Meeting of The Menopause Society.

Type 2 diabetes has emerged as a possible risk factor contributing to the development of dementia, but one class of agents used to treat the disease may provide greater protective effects, study results published in BMJ showed.

Once-weekly insulin efsitora alfa provided similar reductions in HbA1c as once-daily insulin degludec among insulin-naive adults with type 2 diabetes and adults with type 1 diabetes previously receiving a basal and bolus insulin analog.

The FDA has granted breakthrough therapy designation to Arrowhead Pharmaceuticals’ plozasiran, coupled with diet, to decrease triglycerides in patients with familial chylomicronemia syndrome, according to a company release.

Some types of endocrine-disrupting chemicals may act as kisspeptin or gonadotropin-releasing hormone receptor agonists and could induce early puberty for children, according to in vitro findings published in Endocrinology.

A lack of menopause education for health care professionals has had a direct impact on midlife women seeking care, and a new initiative from The Menopause Society aims to bridge a wide gap in knowledge and training.

Vaginal estrogen, vaginal dehydroepiandrosterone, oral ospemifene and vaginal moisturizers result in short-term improvements in vaginal atrophy symptoms, known as genitourinary syndrome of menopause, but more long-term data are needed.

Most adults who had uncontrolled Graves’ disease on antithyroid drugs responded to once-weekly subcutaneous batoclimab, according to top-line results released by Immunovant.